<DOC>
	<DOCNO>NCT03091543</DOCNO>
	<brief_summary>To investigate effect four single oral dos BIA 6-512 ( 25 mg , 50 mg , 100 mg 200 mg ) levodopa pharmacokinetics administer combination single-dose control release levodopa/benserazide 100/25 mg ass tolerability safety four single oral dos BIA 6-512 ( 25 mg , 50 mg , 100 mg 200 mg ) administer combination single-dose control release levodopa/benserazide 100/25 mg .</brief_summary>
	<brief_title>Tolerability , Safety Pharmacokinetics Four Single-doses BIA 6-512 ( Trans-resveratrol ) Their Effect Levodopa Pharmacokinetics</brief_title>
	<detailed_description>Single centre , double-blind , randomise , placebo-controlled , crossover study five single-dose treatment period , washout period dose 5 day . In five consecutive treatment period , eligible subject admit UFH day prior receive study medication . On morning dosing day , subject receive BIA 6-512/Placebo concomitantly Madopar® HBS 125 fasting condition ( least 8 hour ) remain UFH least 24 h post-dose ; , discharge return next period follow-up visit . Blood sample assay plasma BIA 6-512 , levodopa 3-O-methyldopa ( 3-OMD ) take follow time : pre-dose , ¼ , ½ , 1 , 1½ , 2 , 3 , 4 , 6 , 9 , 12 , 16 24 hour post-dose .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Benserazide , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination ( include neurological examination ) , 12lead ECG . Subjects clinical laboratory test within normal reference value . Subjects negative HBsAg , antiHCVAb HIV1 HIV2 Ab test screen . Subjects negative alcohol drug abuse screen admission treatment period . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . ( If female ) She negative pregnancy test screen admission treatment period . Subjects conform inclusion criterion , OR Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 21 unit alcohol week . Subjects significant infection know inflammatory process screen and/or first admission . Subjects acute gastrointestinal symptom time screen and/or first admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use prescription overthecounter medication within 2 week first admission . Subjects use investigational drug and/or participate clinical trial within 4 month first admission . Subjects donate and/or receive blood blood product within previous 4 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>